Speaker Profile

Ph.D., Vice President, Business Development, Synthego

Jason Steiner, Ph.D., leads Synthego’s business strategy and partnerships to enable biotech and pharmaceutical companies to leverage Synthego’s genome engineering platform to accelerate research, discovery, and development of gene therapeutics. Before Synthego, Steiner spent several years in the clinical genomics space commercializing liquid biopsy technologies in reproductive genetics and oncology. He holds a doctoral degree in materials science engineering from the University of California, San Diego, where his research focused on the development of nanoparticle delivery systems for therapeutics and diagnostics in oncology. Steiner’s commercial experience spans across market development and product launches across four continents, building and scaling commercial organizations across marketing, product development, sales, and business development. As an example, during his tenure at Natera, the company’s revenue nearly quadrupled. Steiner also has served as the CEO of a non-profit entity focused on entrepreneurship. His dedication to biotechnology is inspired by mission-driven travels, writing, and business ventures.

Emerging Therapeutics Showcase:

Dr. Jason Steiner, Head of Business Strategy at Synthego, a leading genome engineering company focused on accelerating therapeutic discovery and development will discuss the impact of new genomic engineering technologies on economics, timelines, and scope of traditional pharmaceutical development in contrast with the rise of cellular and genetic therapies.

Flipping The Development Funnel -- How Genome Engineering Is Disrupting Therapeutics Discovery And Development

 Session Abstract – PMWC 2020 Silicon Valley

The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.